Destiny Pharma PLC (AIM:DEST, OTC:DTTYF), the clinical-stage biotechnology firm focused on anti-infectives, has announced a meeting for analysts and investors to discuss its XF product pipeline.
Scheduled for 17 October at 2:00 pm BST, the meeting will be held at the offices of the corporate broker Cavendish in London and will also offer a virtual attendance option.
CEO Chris Tovey will lead the two-hour session, featuring presentations from the management team and external experts like Professor Mark Wilcox and Dr Alex Mericli.
The event aims to shed light on surgical site infections and on-the-ground realities in healthcare settings. No new material disclosures are expected.